TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2033528
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine gluconate (CHX) rinse, 15 ml b.i.d. for 7 weeks (2 weeks before crown preparation, 3 weeks during provisional crown placement, 2 weeks after definitive crown cementation)
Study: 2033528
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal oral hygiene without CHX)
Study: 26654154
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC) 600 mg, three times a day for 24 weeks
Study: 26654154
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg, three times a day for 24 weeks
Study: 24928634
Drug: EGFR stages
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFR stages >90 ml min‐1 1.73 m‐2
Study: 24928634
Drug: EGFR stages
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFR stages <60 ml min‐1 1.73 m‐2
Study: 24928634
Drug: EGFR stages
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFR stages <45 ml min‐1 1.73 m‐2
Study: 16247062
Drug: Epley procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Epley procedure with self-treatment
Study: 16247062
Drug: self-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: self-treatment
Study: 10939030
Drug: Epirubicin 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 150 mg/m2-cisplatin (group A)
Study: 10939030
Drug: Epirubicin 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 180 mg/m2-cisplatin (group B)
Study: 8748403
Drug: Daily lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily lithium carbonate treatment (700 mg)
Study: 8748403
Drug: Alternate-day lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day lithium carbonate treatment (1200 mg)
Study: 1710167
Drug: ThioTEPA at
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ThioTEPA at 75 mg/m2
Study: 1710167
Drug: ThioTEPA at
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ThioTEPA at 65 mg/m2
Study: 1710167
Drug: ThioTEPA pharmacokinetics
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ThioTEPA pharmacokinetics
Study: 1710167
Drug: TEPA pharmacokinetics
Normalized name: Tepadina
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TEPA pharmacokinetics
Study: 7018798
Drug: Methandienone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methandienone (100 mg/day)
Study: 31017453
Drug: Traditional and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional and Complementary Medicine (T&CM) interventions in addition to nicotine replacement therapy (NRT) and counseling
Study: 31017453
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy (NRT) and counseling
Study: 27570900
Drug: Metacognitive Reflection
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacognitive Reflection and Insight Therapy (MERIT) - 12 sessions
Study: 22755543
Drug: Sevoflurane plus
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane plus low-dose remifentanil (Group SR)
Study: 18041570
Drug: 4 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml/kg of hypertonic-hyperoncotic solution (7.2% NaCl/10% dextran)
Study: 16120066
Drug: Indinavir alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir alone or in combination with ritonavir
Study: 10599886
Drug: Wild-type IL-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wild-type IL-4 receptor
Study: 7476738
Drug: Inhalation anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anesthesia using N2O:O2, halothane, d‐tubocurarine (n = 11)
Study: 7476738
Drug: Inhalation anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anesthesia using N2O:O2, halothane, d‐tubocurarine, and supplemented with epidural analgesia (EA) (n = 11)
Study: 7476738
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) using ketamine 10‐30 ug.kg‐1.min‐1, propofol 2 mg.kg‐1.h‐1, d‐tubocurarine, and supplemented with continuous EA (n = 6)
Study: 7476738
Drug: TIVA using
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIVA using ketamine 20‐50 ug.kg‐1.min‐1, midazolam in increments of 1.5 to 5 mg, and supplemented with intermittent EA (n = 5)
Study: 6752876
Drug: Ketoprofen (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (300 mg/day)
Study: 30176553
Drug: BCS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCS plus postoperative radiation therapy (XRT)
Study: 25259787
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus low-dose rosiglitazone (MR)
Study: 21180001
Drug: RelyX ARC
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RelyX ARC (ARC, 3M ESPE) with 32% phosphoric acid treatment
Study: 17708284
Drug: Low-dose anticancer
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose anticancer drugs (MMC 2-8 mg, EPI 5-10 mg, CBP 100 mg)
Study: 17708284
Drug: Conventional-dose anticancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose anticancer drugs (MMC 10 mg, EPI 40 mg, CBP 300 mg)
Study: 12172338
Drug: Reboxetine 8
Normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine 8 to 10 mg per day
Study: 8271293
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of beta carotene per day
Study: 8271293
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g ascorbic acid plus 400 mg alpha tocopherol per day
Study: 8271293
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three agents combined (25 mg beta carotene, 1 g ascorbic acid, 400 mg alpha tocopherol)
Study: 8271293
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three agents combined
Study: 2536257
Drug: Dideoxycytidine 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dideoxycytidine 0.06 mg/kg
Study: 2536257
Drug: Dideoxycytidine 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dideoxycytidine 0.03 mg/kg
Study: 2536257
Drug: Dideoxycytidine 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dideoxycytidine 0.01 mg/kg
Study: 2536257
Drug: Dideoxycytidine 0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dideoxycytidine 0.005 mg/kg
Study: 29330230
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention including bimonthly behavioural counselling, sit-stand desk attachment, wrist-worn activity-prompting device, cognitive behavioural therapy for LBP self-management
Study: 22800624
Drug: Low-dose iron
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose iron supplementation (1 mg×kg⁻¹×d⁻¹) for 2 months
Study: 3579819
Drug: Alcohol at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol at ground level (100-proof vodka mixed with juice, 2.2 ml X kg-1 of body weight)
Study: 31840620
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid (FA) at 10 mg FA/kg dietary DM
Study: 31840620
Drug: Branched-chain volatile
Normalized name: coal tar pitch volatiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched-chain volatile fatty acids (BCVFA) at 5 g BCVFA/kg dietary DM
Study: 31840620
Drug: Combined addition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined addition of FA and BCVFA (10 mg/kg DM of FA and 5 g/kg DM of BCVFA)
Study: 23475448
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO), twice-daily sessions for 90 minutes at 2.5 ATA, 5 days a week for 2 weeks.
Study: 21981360
Drug: 532-nm KTP
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 532-nm KTP laser treatment (once weekly)
Study: 21981360
Drug: 532-nm KTP
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 532-nm KTP laser treatment (twice weekly)
Study: 2097909
Drug: Topical benzocaine
Normalized name: benzocaine Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzocaine 20%
Study: 19769421
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lidocaine, tetracaine, and phenylephrine
Study: 19769421
Drug: Topical anesthetics
Normalized name: topical anesthetics (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthetics (both)
Study: 15564204
Drug: Itraconazole plus
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole plus lactobacillus preparation for 8 weeks
Study: 15564204
Drug: Lactobacillus preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus preparation alone for 8 weeks
Study: 6228469
Drug: Heat-inactivated hepatitis
Normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-inactivated hepatitis B vaccine (3 micrograms-HBsAg)
Study: 6228469
Drug: Heat-inactivated hepatitis
Normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-inactivated hepatitis B vaccine
Study: 24187861
Drug: Integrated Chinese-Western
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Chinese-Western therapy (injection and prescriptions of Chinese medicine based on Traditional Chinese Medicine syndrome differentiation, combined with Western treatment)
Study: 24187861
Drug: Western therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western therapy alone (chemotherapy, supportive treatment, and symptomatic treatment)
Study: 24187861
Drug: Integrated Chinese-Western
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Chinese-Western therapy
Study: 21264527
Drug: Anti-adrenergic medications
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-adrenergic medications
Study: 15111772
Drug: Doxorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg/m(2)) followed by Paclitaxel (200 mg/m(2) over 3 h)
Study: 15111772
Drug: Doxorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg/m(2)) followed by Cyclophosphamide (600 mg/m(2))
Study: 9625042
Drug: Sodium dodecyl
Normalized name: Sodium dodecyl sulfate
DrugBank: Sodium lauryl sulfate (DB00815)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium dodecyl sulfate‐agarose gel electrophoresis (SDS‐AGE)
Study: 9625042
Drug: Routine agarose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine agarose gel electrophoresis (AGE)
Study: 18070142
Drug: Nitroglycerine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerine infusion
Study: 2512162
Drug: Intermittent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent administration of NTG 20 mg (24 h)‐1 patches with a 12-hour nitrate-free interval
Study: 2512162
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with NTG 20 mg (24 h)‐1 patches
Study: 26495916
Drug: CHO‐loading (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO‐loading (400 ml Nutricia pre‐op®) 2 hours prior to surgery
Study: 19919976
Drug: SLV320 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLV320 10 mg
Study: 16798663
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Simvastatin + Celiprolol)
Study: 14747191
Drug: Breastfeeding compounds
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breastfeeding compounds
Study: 11031342
Drug: Macrolide antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macrolide antibiotic treatment (n = 11)
Study: 11031342
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (n = 7)
Study: 3538922
Drug: Thai Government
Normalized name: Thai galangal extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thai Government Pharmaceutical Organization (GPO) antivenom
Study: 3538922
Drug: Twyford Pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Twyford Pharmaceutical antivenom
Study: 27231160
Drug: Stents-combination (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stents-combination (Group I)
Study: 18662172
Drug: Daptomycin at
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin at 10 mg/kg every 24 h for 4 days
Study: 18662172
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care therapy with vancomycin or semi-synthetic penicillin
Study: 2209033
Drug: No weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: No weekly change (NWC)
Study: 31132302
Drug: Mindfulness module
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindfulness module of dialectical behavioural therapy (DBT‐M)
Study: 11429362
Drug: Multiple injection
Normalized name: sodium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple injection technique
Study: 9894701
Drug: Naloxone (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.02 mg/kg)
Study: 7994448
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg oid
Study: 2680083
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of phenylpropanolamine HCl (PPA)
Study: 5551272
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron 30 mg once daily
Study: 5551272
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron 60 mg once daily
Study: 5551272
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron 120 mg once daily
Study: 5551272
Drug: Parenteral iron
Normalized name: Iron, parenteral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral iron 1 g followed by oral iron 60 mg
Study: 29677345
Drug: 60-mg caffeine
Normalized name: caffeine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-mg caffeine group
Study: 29677345
Drug: 120-mg caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120-mg caffeine group
Study: 29677345
Drug: 180-mg caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180-mg caffeine group
Study: 29677345
Drug: 0-mg group
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0-mg group (control)
Study: 28643901
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (1000 mg iron)
Study: 26683949
Drug: DAPT +
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT + atorvastatin 20 mg daily + lansoprazole 30 mg daily (Group A)
Study: 26683949
Drug: DAPT +
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT + atorvastatin 20 mg daily (Group B)
Study: 26683949
Drug: DAPT +
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT + lansoprazole 30 mg daily (Group C)
Study: 20843556
Drug: lithium (1‐1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: lithium (1‐1.2 mEq/L) + tamoxifen 80 mg/day
Study: 20843556
Drug: lithium (1‐1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: lithium (1‐1.2 mEq/L) + placebo
Study: 18939399
Drug: Intravenous Tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Tramadol (100 mg) and IV hyoscine N butylbromide (20 mg)
Study: 18939399
Drug: IV hyoscine
Normalized name: HYOSCINE HYDROBROMIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV hyoscine N butylbromide (20 mg) only
Study: 8885906
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (0.625 mg) and medroxyprogesterone (10 mg) cyclically for 3 months
Study: 1520045
Drug: Gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 600 mg twice daily for 6 weeks
Study: 1520045
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 mg twice daily for 6 weeks
Study: 6500763
Drug: Isofezolac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isofezolac (50 mg) alone
Study: 6500763
Drug: Isofezolac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isofezolac (50 mg) with aspirin (1 g)
Study: 6500763
Drug: Isofezolac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isofezolac (50 mg) with phosphalugel (11 g aluminum phosphate)
Study: 30895459
Drug: Suspension with
Normalized name: SUSPENSION WITH PREFILLED APPLICATOR(ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension with prior climbing
Study: 30895459
Drug: Suspension without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suspension without prior climbing
Study: 30895459
Drug: Post-suspension recovery
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-suspension recovery
Study: 26768572
Drug: Ebola vaccine
Normalized name: ebola vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebola vaccine intervention
Study: 22569288
Drug: Daily atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily atorvastatin (QD)
Study: 22569288
Drug: Alternate-day atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day atorvastatin (QOD)
Study: 12910715
Drug: KC-404 sustained
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: KC-404 sustained release tablets (20 mg)
Study: 12910715
Drug: KC-404 capsules
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: KC-404 capsules (20 mg)
Study: 28816883
Drug: 0.01 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mg/kg IV atropine
Study: 19948946
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice with 400 mg nilotinib
Study: 19948946
Drug: Water with
Normalized name: sterile water with electrolytes injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water with 400 mg nilotinib
Study: 15819283
Drug: Etoricoxib, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib, 30 mg once daily
Study: 15819283
Drug: Ibuprofen, 800
Normalized name: Ibuprofen, 800 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen, 800 mg 3 times daily
Study: 6419596
Drug: Auranofin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auranofin (6 mg per day)
Study: 6419596
Drug: D-penicillamine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine (500 mg per day)
Study: 30709557
Drug: Combined aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined aprepitant therapy (aprepitant plus dexamethasone and tropisetron)
Study: 30709557
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (dexamethasone and tropisetron)
Study: 26921267
Drug: Mindfulness-Based Stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Stress Reduction (MBSR) as an add-on to treatment as usual (TAU)
Study: 26921267
Drug: Psychoeducational programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational programme (FibroQoL) as an add-on to treatment as usual (TAU)
Study: 22127729
Drug: Alendronate treatment
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate treatment group
Study: 17370037
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m2 over 1 h on day 1 followed by ifosfamide 5 g/m2 divided over days 1 and 2 (2.5 g/m2/day over 1 h), recycled every 21 days with prophylactic G-CSF administration from day 3 until a neutrophil count >10,000/microl.
Study: 8586834
Drug: Cyclosporin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (10 mg/kg twice a day orally) with exogenous angiotensin II (1 ng/kg per min intravenously)
Study: 8586834
Drug: Cyclosporin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (10 mg/kg twice a day orally) with frusemide (40 mg/day orally for 2 days)
Study: 8586834
Drug: Cyclosporin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (10 mg/kg twice a day orally)
Study: 2710909
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (N = 30)
Study: 2710909
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment, N = 20)
Study: 31542980
Drug: Nicotine inhaler
Normalized name: nicotine Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine inhaler (4 mg deliverable)
Study: 31542980
Drug: Perceived nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perceived nicotine administration